Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences

Wednesday, December 17, 2008 General News J E 4
CARLSBAD, Calif., Dec. 17 Isis Pharmaceuticals,Inc. (Nasdaq: ISIS) announces the following webcast:

If you are unable to participate during the live event, a replay of thewebcast will be available for a limited time at


Isis is exploiting its expertise in RNA to discover and develop noveldrugs for its product pipeline and for its partners. The Company hassuccessfully commercialized the world's first antisense drug and has 19 drugsin development. Isis' drug development programs are focused on treatingcardiovascular and metabolic diseases. Isis' partners are developingantisense drugs invented by Isis to treat a wide variety of diseases. IbisBiosciences, Inc., Isis' majority-owned subsidiary, is developing andcommercializing the Ibis T5000(TM) Biosensor System, a revolutionary system toidentify infectious organisms. Isis is a joint owner of Regulus TherapeuticsLLC, a joint venture focused on the discovery, development andcommercialization of microRNA therapeutics. As an innovator in RNA-based drugdiscovery and development, Isis is the owner or exclusive licensee of over1,500 issued patents worldwide. Additional information about Isis isavailable at Abbott's exercise of its option to purchase Ibis Biosciences, a subsidiary of Isis. Total acquisition price will be $215 million. When: Wednesday, December 17, 2008 at 8:30 a.m. ET / 5:30 a.m. PT Where: How: Live on the Internet. Simply log onto our Web site listed above. Contacts: Kristina Lemonidis Associate Director, Corporate Development (760) 603-2490 Amy Blackley, Ph.D. Manager, Corporate Communications (760) 603-2772

SOURCE Isis Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Ochsner Health System Protects Private Health Info...
NicOx' Naproxcinod Shows Robust Blood Pressure Res...